BIIB-028

• UNSPSC Description:

  BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation[1][2].

• Target Antigen:

  HSP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/biib-028.html

• Smiles:

  CC(C(OC)=C(C)C=N1)=C1CN2C3=NC(N)=NC(Cl)=C3C(C#CCCOP(O)(O)=O)=C2

• Molecular Weight:

  465.83

• References & Citations:

  [1]Soga S, et al., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19(3):366-76.|[2]Rahimi M N. Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90): from design and synthesis to cellular drug delivery[D]. UNSW Sydney, 2020.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 1

• CAS Number:

  911398-13-5